Articles tagged with Cancer Medication
A pre-clinical study has revealed that combining OX40 agonist antibody and GSK2366771 may enhance the immune system's ability to kill melanoma tumors deficient in PTEN. The combination appears to 'step on the gas', revving up T cells and providing extra power to more efficiently kill cancer cells.
Researchers at the Abramson Cancer Center have discovered promising immunotherapy combinations for treating glioblastoma, head and neck cancer, and pancreatic cancer. CAR T cell therapy combined with checkpoint inhibitors has shown enhanced effectiveness in glioblastoma, while targeting a novel immune checkpoint in head and neck cancer...
Researchers have systematically mapped connections between 625 breast and ovarian cancer genes and nearly every FDA-approved chemotherapy for these cancers. The map reveals new genetic factors that determine the response of tumor cells to common classes of chemotherapy treatment.
Scientists developed a high-speed microscopy platform that can measure tumor sensitivity to drugs in hours, rather than days, and has shown promising results in treating melanoma
Researchers used single-cell imaging to study how melanoma cells evade drug action and acquire resistance to BRAF-inhibitor dabrafenib. The study found that 10% of treated cells reactivated the MAPK signaling pathway within 2-3 days, allowing them to signal through the pathway even in the presence of BRAF inhibition.
Researchers found that giving patients a single dose of anti-PD-1 therapy before surgery can predict tumor response and patient outcomes. The study also revealed that immune cells active against cancer were present in patients with longer recurrence-free survival.
A phase I clinical trial of BLU-667, a novel precision-targeted drug, reports significant durable disease control in patients with RET-driven cancers. The study reveals an overall response rate of 37% for RET-driven cancers, with responses of 45% for non-small cell lung cancer.
A recent study by Tel Aviv University and Harvard University researchers highlights the challenges of nanoparticle-based cancer-targeting strategies. They suggest ways to refocus collaborative work, emphasizing personalized nanocarriers based on cancer type and biomarker profile.
Two targeted therapies, MLN128 and CB-839, individually target the metabolism of key nutrients glucose and glutamine, respectively, to treat squamous cell carcinomas of the lung. Researchers found that when used in combination, these drugs could reduce tumor growth in aggressive lung cancer.
Priya Prasad, MD, has received the David L. Rimoin Inspiring Excellence Award for her platform presentation on population-based hereditary cancer risk assessment during screening mammography. The award recognizes her commitment to enhancing the appropriate utilization of screening for hereditary cancers.
A clinical trial is underway to test an experimental peptide drug, ALRN-6924, which has shown promise against acute myeloid leukemia (AML) by tripling the median survival rate in animal models. The drug targets p53 and MDMX/MDM2 proteins, blocking tumor growth in both mature and immature AML cells.
Researchers identified PDE5 inhibitors, like Viagra, as potential treatments for glioblastoma multiforme and other rare cancers. The study suggests these drugs may increase permeability to improve drug delivery to brain tumors.
Researchers found that adding trastuzumab to chemotherapy regimen for women with uterine serous carcinoma significantly increased progression-free survival time, from an average of eight months to 12.6 months. The treatment showed promise in reducing tumor growth and improving overall survival.
Researchers aim to eradicate chronic lymphocytic leukemia (CLL) by targeting specific cancer cells. The team has discovered a binding site on CLL lymphocytes that pulls antibodies into the cells in minutes, allowing for more effective treatments.
Researchers have discovered a new class of drug that targets treatment-resistant cancers by inhibiting the action of enzyme CDK7. Early lab-based tests showed minimal side effects and successful suppression of tumour growth in various cancer types.
A University of North Carolina-led study has found that physicians who received payments from pharmaceutical companies were more likely to prescribe those companies' drugs for two cancer types. The study analyzed prescriptions for Medicare patients with metastatic renal cell cancer and chronic myeloid leukemia, finding a significant as...
Researchers used machine learning to classify abnormal protein activity in tumors, identifying potential 'hidden responders' who may benefit from specific therapies. The study combined genetic data with machine learning approaches to predict response to inhibitors affecting cancer cells with overactive Ras signaling.
Researchers from the University of Cambridge identified key anti-cancer drugs that could be used to treat transmissible cancers in Tasmanian devils. The study found that the two types of cancer are similar and likely arose due to the devils' susceptibility to developing these diseases.
A study found that only 16% of respondents were aware of drug shortages, and those with a personal history of cancer were more likely to be aware. Most respondents wanted to be informed about substitution due to shortages and would transfer care to avoid major differences in efficacy.
A promising class of drugs, known as CD40 monoclonal antibodies, could be the spark needed to light the fire in the immune system of patients who don't respond to cancer immunotherapies. These drugs activate antigen-presenting cells to prime tumor-specific T cell responses.
Researchers identified two transmissible cancers in Tasmanian devils, suggesting a genetic problem with cell regulation that increases disease risk. The effective drugs discovered may also play a role in wound repair pathways, potentially linked to the devils' frequent facial injuries.
Researchers found all frailty scores associated with future mortality, and some linked to cardiovascular disease but none to cancer. Certain scores outperform others for all-cause mortality and cardiovascular health outcomes.
The PDX Finder is a free global portal for cancer models, offering over 1900 clinically relevant models from multiple repositories. Researchers can search and submit their own models to accelerate collaborative research and time-saving.
A clinical trial has shown that a combination of checkpoint inhibitors and an immune stimulation drug can control the progression of non-small cell lung cancer. The treatment was administered in an outpatient setting and demonstrated significant prolonged survival in patients.
Researchers from Eindhoven University of Technology developed a cheaper production method for the cancer drug Z-endoxifen, using a paper filter purification process inspired by filtering coffee. This approach reduces production costs to 1,000 times lower than the previous method.
Researchers created patient-specific bladder cancer organoids that mimic actual tumors, allowing for testing of multiple drugs and predicting individual response to treatment. The use of these personalized models may improve understanding of the genomics of bladder cancer and develop new therapies.
The Cancer Genome Atlas project has identified 300 genes that drive tumor growth and found that just over half of tumors carry genetic mutations targetable by existing therapies. The research provides unprecedented understanding of cancer's genetic basis, enabling better-informed clinical trials and future treatments.
The Translational Genomics Research Institute (TGen) will receive $450,000 to fund a clinical trial for a newly developed ovarian cancer drug treatment, thanks to Colleen's Dream Foundation. The foundation has funded TGen in the past and has awarded over $1.2 million in grants to 27 institutions.
Researchers at Cold Spring Harbor Laboratory discovered that cancer cells lacking tumor-suppressor protein PTEN are vulnerable to mitochondrial inhibitors, which induce them to consume glucose and quickly run out of energy. This finding suggests that such drugs could eliminate cancer cells while leaving healthy cells intact.
A combination of EGFR and TNF inhibitors effectively blocks cancer's escape route, making it sensitive to treatment. The two-drug strategy has the potential to work for all non-small cell lung cancers, offering a new hope for patients.
Researchers identified nearly 200 mutations in non-coding DNA that play a functional role in cancer, providing potential molecularly targeted therapeutics. These mutations could represent new targets for cancer drugs and may help explain the diversity of genetic mutations in tumors.
Researchers have engineered brewer's yeast to produce noscapine, a potential cancer drug with fewer side effects than conventional chemotherapy. The engineered yeast strain produced 2.2 mg/L noscapine after optimization, paving the way for large-scale commercial production.
Researchers at Massachusetts General Hospital report promising preclinical results against uniformly fatal tumor, finding that combining two cancer immunotherapy drugs significantly prolongs survival time. The treatment changes a population of immunosuppressive T cells into a type that could enhance an antitumor immune response.
Researchers successfully treat KRAS-driven lung cancer by targeting insulin and IGF-1 signaling, identifying metabolic vulnerabilities. The study shows that completely blocking the pathway can slow tumor growth, but a second step is needed to fully suppress it.
A recent study found that cancer survivors were more likely to be insured, yet still reported greater challenges in accessing and affording healthcare compared to adults without cancer. The proportion of cancer survivors experiencing these issues decreased over time since the Affordable Care Act (ACA) was signed into law.
Larotrectinib, a new pediatric cancer drug targeting the TRK gene fusion, showed an unprecedented 93 percent response rate in patients tested. The drug has been effective in treating rare pediatric cancers such as infantile fibrosarcoma and papillary thyroid cancer.
A study published in the Journal of Clinical Oncology found that taking a standard prostate cancer drug with food can boost its impact and lower costs. By decreasing the daily dose, preventing digestive issues, and cutting costs by 75 percent, patients could save up to $300,000 per month.
Researchers at the University of Johannesburg have discovered a new family of economical silver-based complexes that show very promising results against various human cancers. These complexes, such as UJ3, are selective and have low toxicity, making them a potential alternative to existing chemotherapy drugs.
Scientists at Michigan State University have discovered a promising new drug that targets the c-Myc gene, which is linked to obesity and various cancers. The drug, I-BET-762, delays the development of existing cancers by inhibiting critical proteins involved in cancer cell growth.
A recent study found that receptivity to e-cigarette advertising significantly increased the odds of 12-21 year-olds who have never smoked trying cigarette smoking within a year. This association was independent of receptivity to cigarette advertising.
Researchers found that changing the scheduling of drug administration can improve outcomes in mouse models of melanoma, leading to more complete responses. A combination of MEK inhibitor given continuously with intermittent CDK4/6 inhibitor was the most effective schedule in mice.
A meta-analysis by Case Western Reserve University researcher Nathan Berger reveals that obesity increases risk of 13 different cancers in young adults, with certain cancers now reported in people under 50. Obesity can alter cellular mechanisms promoting cancer and increase cancer rates as it rises among younger demographics.
A Singapore-led team of Asian cancer researchers has won the prestigious AACR Team Science Award for their groundbreaking work on cancers prevalent in Asia. The team's research has identified new genes and pathways, translated findings into clinical trials, and informed government policies.
A new antimalarial drug delivery system using MCM-41 has been developed, demonstrating a long release time of one week or longer and increasing treatment efficiency by 20 and 240 times compared to traditional medications.
Researchers identified new genetic mutations in cancer cells that promote survival and resistance to treatment. The study found that no two cancers were genetically identical, even among those with similar characteristics.
Researchers at Houston Methodist have identified a compound that prevents breast cancer cells from spreading to the brain. Edelfosine, an investigational leukemia treatment, has been shown to stop cancer stem cells from growing once they reach the brain. This finding offers new hope for treating metastatic brain disease.
A new study using Medicare claims data found that finasteride significantly reduces prostate cancer risk over a period of 16 years, with a 21% decrease in risk compared to those on a placebo. This long-term benefit is twice as long as previously recorded.
Researchers established two new adrenal cancer cell lines and mouse models to test novel treatments, identifying PBK as a key target. A patient treated with pembrolizumab showed remarkable response with 77% tumor reduction, while a humanized mouse model also responded to the immunotherapy.
A new study by Dartmouth Health suggests that e-cigarette use may be more harmful than beneficial, particularly among adolescents and young adults. The research found that e-cigarettes could lead to over 1.5 million years of life lost due to increased smoking rates among youth.
Researchers have created BN/Ag hybrid nanomaterials that demonstrate effectiveness as catalysts, antibacterial agents, and drug delivery systems for treating oncological diseases. The hybrids show high potential for cancer therapy and water disinfection, offering a new approach to combatting these threats.
Moffitt researchers used single-cell imaging and mathematical modeling to determine the most important drug characteristics for efficient uptake by tumor cells. They found that drugs with different diffusion rates and concentrations bind effectively to cells based on their distance from blood vessels and density of drug receptors.
Researchers have identified 110 genes linked to an increased risk of breast cancer, including 32 genes related to survival rates. The study uses a genetic technique to analyze DNA regions and identify specific genes involved in raising a woman's risk.
Researchers discovered that inhibiting autophagy with the help of FOXO3a molecule can push cancer cells into apoptosis. The study found that combining autophagy inhibition with a drug called Nutlin increases PUMA production, leading to cell death.
A study found that ACE-inhibitors and beta blockers can reduce the risk of heart damage in women receiving anthracycline-based chemotherapy alongside trastuzumab. However, these medications were not effective for those without a history of anthracycline exposure.
Researchers are testing a new combination of cirmtuzumab and ibrutinib to eradicate leukemias and other blood cancers. The trial aims to determine the safety and effectiveness of the duo's treatment, which could potentially lead to complete remissions without continuous therapy.
Scientists at Cold Spring Harbor Laboratory have discovered a way to rein in an overactive protein that drives some aggressive leukemias. The team's CRISPR-based system identifies two enzymes, LKB1 and salt-inducible kinase, as critical for the survival of certain AML cells.
Researchers found a 'stop sign' protein that prevents healthy cells from sorting material, leading to unregulated growth in cancerous cells. This discovery opens the door to designing drugs that block PIP-stop formation by kinase enzymes, targeting difficult-to-treat cancers.
A recent study published in The BMJ questioned the underlying evidence for current US cancer treatment guidelines. Researchers found that these guidelines often rely on low-quality or no evidence at all. The study highlights concerns about the justification of costly and toxic cancer drugs based on weak evidence.
A new slow-release hydrogel has been developed to aid immunotherapy for cancer, providing a continuous dose of immunotherapy drugs to activate the immune system. The hydrogel, called STINGel, was tested in lab cultures and in vivo trials, showing promise in killing cancer cells and preventing further implantation of cancer cells.
Scientists at Greehey Children's Cancer Research Institute have found a new mechanism by which BRCA1 can be rendered dysfunctional in Ewing sarcoma. The study reveals that the mutant oncogene produced by the fusion oncogene traps BRCA1, preventing it from repairing genetic damage.